HomeCompareIFUS vs MRK

IFUS vs MRK: Dividend Comparison 2026

IFUS yields 8492.57% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IFUS wins by $11041986035131172.00M in total portfolio value
10 years
IFUS
IFUS
● Live price
8492.57%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11041986035131172.00M
Annual income
$10,792,008,505,664,056,000,000.00
Full IFUS calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — IFUS vs MRK

📍 IFUS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIFUSMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IFUS + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IFUS pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IFUS
Annual income on $10K today (after 15% tax)
$721,868.37/yr
After 10yr DRIP, annual income (after tax)
$9,173,207,229,814,447,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, IFUS beats the other by $9,173,207,229,814,447,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IFUS + MRK for your $10,000?

IFUS: 50%MRK: 50%
100% MRK50/50100% IFUS
Portfolio after 10yr
$5520993017565586.00M
Annual income
$5,396,004,252,832,028,000,000.00/yr
Blended yield
97.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

IFUS
No analyst data
Altman Z
7.4
Piotroski
5/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IFUS buys
0
MRK buys
0
No recent congressional trades found for IFUS or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIFUSMRK
Forward yield8492.57%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$11041986035131172.00M$56.8K
Annual income after 10y$10,792,008,505,664,056,000,000.00$9,798.13
Total dividends collected$11025302406276466.00M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IFUS vs MRK ($10,000, DRIP)

YearIFUS PortfolioIFUS Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$859,957$849,256.90$11,206$366.19+$848.8KIFUS
2$69,174,764$68,254,610.41$12,650$502.35+$69.16MIFUS
3$5,205,220,238$5,131,203,240.18$14,407$694.19+$5205.21MIFUS
4$366,419,711,261$360,850,125,605.98$16,585$967.82+$366419.69MIFUS
5$24,132,183,173,475$23,740,114,082,425.72$19,342$1,363.89+$24132183.15MIFUS
6$1,487,045,477,053,427$1,461,224,041,057,809.20$22,913$1,947.19+$1487045477.03MIFUS
7$85,742,407,458,414,640$84,151,268,797,967,470.00$27,662$2,823.89+$85742407458.39MIFUS
8$4,626,441,795,368,287,000$4,534,697,419,387,782,700.00$34,159$4,173.35+$4626441795368.25MIFUS
9$233,623,859,315,062,280,000$228,673,566,594,018,200,000.00$43,337$6,308.80+$233623859315062.25MIFUS
10$11,041,986,035,131,173,000,000$10,792,008,505,664,056,000,000.00$56,776$9,798.13+$11041986035131172.00MIFUS

IFUS vs MRK: Complete Analysis 2026

IFUSStock

Impact Fusion International, Inc. engages in the business of marketing products in the health and wellness sector. The company focuses on the invention, development, and marketing of its proprietary products worldwide for the health of humans and animals. The company's products include Nutri-Mastic that supports digestive function, the immune system, vital organ health, healthy blood cells, and cardiac muscle and heart function; Intact Nutrition herbal health support products; Intact Endurance, which offers nutrients to increase body's optimal energy levels; Pet Intact nutritional supplements; and Equine Intact products. It also sells herbal health support beverages under the Mastic Blast Beverage brand; and alternative proprietary formulation for beef and dairy cattle under the Supreme Gold Plus brand. The company was formerly known as Red Reef Laboratories International, Inc. and changed its name to Impact Fusion International Inc. in April 2009. Impact Fusion International, Inc. was founded in 2002 and is based in Margate, Florida.

Full IFUS Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this IFUS vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IFUS vs SCHDIFUS vs JEPIIFUS vs OIFUS vs KOIFUS vs MAINIFUS vs JNJIFUS vs ABBVIFUS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.